MarketCap
Facebook
X
TelegramEyeGate Pharmaceuticals, Inc. DSO Ratio 2011-2026 | EYEG
Annual DSO Ratio EyeGate Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 2.75 K | 0.66 | 4.07 | 21.2 | 29.4 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.75 K | 0.66 | 562 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Altimmune
ALT
|
7.85 K | $ 3.5 | 4.64 % | $ 308 M |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 221.52 | -0.16 % | $ 5 B |  Danmark |
 |
Heron Therapeutics
HRTX
|
198 | $ 0.8 | 2.5 % | $ 133 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
Incyte Corporation
INCY
|
66.6 | $ 90.82 | 0.04 % | $ 17.7 B | USA |
 |
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
InMed Pharmaceuticals
INM
|
3.83 | $ 0.79 | -3.52 % | $ 1.93 M | Canada |
 |
INmune Bio
INMB
|
60.1 K | $ 1.23 | 5.13 % | $ 22.1 M | USA |
 |
Inovio Pharmaceuticals
INO
|
1.91 K | $ 1.57 | -0.95 % | $ 34.8 M | USA |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
3.1 | - | - | $ 3.74 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
6.83 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Compugen Ltd.
CGEN
|
60.8 | $ 2.13 | 1.91 % | $ 199 M | Israel |
 |
KalVista Pharmaceuticals
KALV
|
475 | $ 16.93 | -0.41 % | $ 841 M | Britain |
 |
CorMedix
CRMD
|
130 | $ 6.35 | 1.6 % | $ 457 K | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.33 | 2.12 % | $ 719 M | Canada |
 |
Kamada Ltd.
KMDA
|
103 | $ 8.33 | 0.97 % | $ 260 M | Israel |